Our ADHD Pipeline – Drug Candidates in Clinical Investigation. Highland's wholly owned subsidiary, Ironshore Pharmaceuticals & Development, Inc. has the

About Herantis Pharma Oyj Herantis Pharma PLC manufactures pharmaceutical products. The Company develops drugs to treat various types of diseases. Herantis Pharma serves customers in Finland.

Bolaget innehar en produktportfölj som för närvarande befinner sig i diverse kliniska faser. Herantis Pharma Plc (HRTIS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile report is published on April 12, 2018 and has 29 pages in it. This market research report provides information about Deals & Alliances (Pharma & Healthcare), Pharma & Healthcare industry. It covers Finland market data and forecasts. Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2015 With confidence toward launching new clinical studies Highlights in January-Dec Herantis Pharma Plc ("Herantis" or the "Company"), an innovative drug development company pioneering new disease modifying and regenerative biologic and gene therapies, announced on 17 December 2020 the result of the offering of new shares (the "Placing Shares") in a private placement to institutional and other qualified investors (the "Placing"). Herantis Pharma Plc (HRTIS) - Financial and Strategic SWOT Analysis Review report is published on May 28, 2020 and has 25 pages in it.

Herantis pharma plc

Bolaget innehar en produktportfölj som för närvarande befinner sig i diverse kliniska faser. Herantis Pharma är ett forskningsbolag. Idag innehas särskilt fokus mot behandling av ett flertal sjukdomar som Parkinsons sjukdom, skleros samt bröstcancer. Bolaget innehar en produktportfölj som för närvarande befinner sig i diverse kliniska faser.

Herantis Pharma Plc. | 1,114 followers on LinkedIn. Herantis Pharma is a publicly listed (HRTIS) innovative clinical stage biotech company with a diverse pipeline of pioneering investigational therapeutics looking to modify the course of debilitating nervous system and lymphatic diseases and break the boundaries of standard therapeutic approaches.

Herantis Pharma Plc ("Herantis" or "Company") announced today that the company has appointed Julie Silber and Gabriela Urquilla of JG Investor Relations AB ("JG-IR") as the new Investor Relations team, as of 1 September 2020. Herantis Pharma Plc (“Herantis” or “Company”) announced today an update on the development of its non-invasive next generation CDNF, or xCDNF. The xCDNF development program was initiated in July 2018 to develop cell-protecting molecules that penetrate the blood-brain barrier, building on the Company’s cumulated expertise on CDNF, Herantis’ lead compound in Parkinson disease.

Herantis Pharma Plc (“Herantis”), an innovativeclinical stage biotechcompany pioneering new disease modifying and regenerative biologic

Herantis Pharma serves customers in Finland. 2020-12-17 18:20:00 Herantis Pharma Oyj: Herantis Pharma Plc launches an accelerated bookbuilding process to raise a minimum of EUR 6.5 million through a private placement of new shares-1,46% | 0,59 MEUR Herantis Pharma Plc Company release, 1 February 2021 at 3:30 p.m. EET The following members have been appointed to Herantis Pharma's Shareholders' Nomination Co Herantis Pharma Plc's Half year financial report January 1-June 30, 2016 (unaudited) Thu, Aug 25, 2016 08:00 CET. Herantis Pharma Plc Company release August 25, 2016 at 9:00am. Development of Lymfactin® and CDNF proceeds as planned Herantis Pharma Plc's Half year financial report January 1-June 30, 2016 (unaudited) Herantis Pharma Oyj: Notice to convene Herantis Pharma Plc's Extraordinary General Meeting of shareholders. 12:30 / 11 November 2020 Herantis Pharma Press release Decisions of Herantis Pharma Plc's Annual General Meeting of shareholders Herantis Pharma Plc Company release 11 April 2016 at 5:00 PM The Annual General Meeting of Shareholders of Herantis Pharm Herantis Pharma Plc. Company Press Release, 25 March 2021 at 08:00 a.m.

Our regenerative medicine drug candidates include i. CDNF biological therapy that acts on the proteostatic mechanisms of disease for the treatment of Parkinson’s disease and other neurodegenerative diseases, and ii. Herantis Pharma Plc is an innovative drug development company breaking the boundaries of standard therapeutic approaches.
Ukraina resa

Herantis Pharma Oyj: Herantis Pharma Published the Annual Report for the Financial Year 2020; 2021-03-25 07:00 · Cision Herantis Pharma Oyj: Herantis Pharma on julkaissut vuoden 2020 vuosikertomuksen; 2021-03-23 18:10 · Cision Herantis Pharma Oyj: NOTICE TO CONVENE HERANTIS PHARMA PLC'S ANNUAL GENERAL MEETING OF SHAREHOLDERS 2021-03-23 · Herantis Pharma Plc. Company release 23 March 2021 at 19:10 p.m. EET. Notice is given to the shareholders of Herantis Pharma Plc to the Annual General Meeting of the Company to be held on 15 April 2021, commencing at 10.00 a.m. (Eastern European Summer Time) at the premises of Krogerus Attorneys Ltd, at the address Unioninkatu 22, 00130 Helsinki, Finland. 2019-08-28 · Herantis Pharma Plc. Company release August 28, 2019 at 9:00am. Herantis Pharma Plc announces half year financial report January 1 - June 30, 2019 (unaudited) Herantis Pharma Plc's Financial Statements Release January 1 - December 31, 2015 With confidence toward launching new clinical studies Highlights in January-Dec Herantis Pharma PlcCompany release August 29, 2018 at 9:00amDrug development progresses in randomized trialsHerantis Pharma Plc's half year financial report Jan 14 timmar sedan · Herantis Pharma Plc. Company release.

Aktiehistorik, Herantis Pharma plc. På skatteverket.se använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Köp aktier i Herantis Pharma Oyj - enkelt och billigt hos Avanza Bank.
Crm 05

News feed of Herantis Pharma. Herantis Pharma är ett forskningsbolag. 2020-12-18 13:45:00 Herantis Pharma Oyj: Herantis Pharma Plc: 2,162,163 new

Namnändringar och notering på lista. År. Kommentarer. Aktien är noterad på First North (sedan Senaste nytt om Herantis Pharma aktie. Herantis Pharma komplett bolagsfakta från DI.se.